Functional and structural alterations of clustered postsynaptic ligand gated ion channels in neuronal cells are thought to contribute to synaptic plasticity and memory formation in the human brain. Here, we describe a novel molecular mechanism for structural alterations of NR1 subunits of the NMDA receptor. In cultured rat spinal cord neurons, chronic NMDA receptor stimulation induces disappearance of extracellular epitopes of NMDA receptor NR1 subunits, which was prevented by inhibiting matrix metalloproteinases (MMPs). Immunoblotting revealed the digestion of solubilized NR1 subunits by MMP-3 and identified a fragment of about 60 kDa as MMPs-activity-dependent cleavage product of the NR1 subunit in cultured neurons. The expression of MMP-3 in the spinal cord culture was shown by immunoblotting and immunofluorescence microscopy. Recombinant NR1 glycine binding protein was used to identify MMP-3 cleavage sites within the extracellular S1 and S2-domains. N-terminal sequencing and site-directed mutagenesis revealed S542 and L790 as two putative major MMP-3 cleavage sites of the NR1 subunit. In conclusion, our data indicate that MMPs, and in particular MMP-3, are involved in the activity dependent alteration of NMDA receptor structure at postsynaptic membrane specializations in the CNS.
References
[1]
Washbourne P, Dityate A, Scheiffele P, Biederer T, Weiner JA, et al. (2004) Cell adhesion molecules in synapse formation. J Neurosci 24: 9244–9249.
[2]
Rao A, Craig AM (1997) Activity regulates the synaptic localization of the NMDA receptor in hippocampal neurons. Neuron 19: 801–812.
[3]
Mu Y, Otsuka T, Horton AC, Scott DB, Ehlers MD (2003) Activity-dependent mRNA splicing controls ER export and synaptic delivery of NMDA receptors. Neuron 40: 581–594.
[4]
Pauly T, Schlicksupp A, Neugebauer R, Kuhse J (2005) Synaptic targeting of NMDA receptor splice variants is regulated differentially by receptor activity. Neurosci 131: 99–111.
[5]
Nong Y, Huang YQ, Ju W, Kalia LV, Ahmadian G, et al. (2003) Glycine binding primes NMDA receptor internalization. Nature 422: 302–307.
[6]
Kuryatov A, Laube B, Betz H, Kuhse J (1994) Mutational analysis of the glycine-binding site of the NMDA receptor: structural similarity with bacterial amino acid-binding proteins. Neuron 12: 1291–1300.
[7]
Furukawa H, Gouaux E (2003) Mechanisms of activation, inhibition and specificity: crystal structures of the NMDA receptor NR1 ligand-binding core. EMBO J 22: 2873–2885.
[8]
Malinow R, Malenka RC (2002) AMPA receptor trafficking and synaptic plasticity. Annu Rev Neurosci 25: 103–126.
[9]
Holmes KD, Mattar PA, Marsh DR, Weaver LC, Dekaban GA (2001) The N-methyl-D-aspartate receptor splice variant NR1-4 C-terminal domain. Deletion analysis and role in subcellular distribution. J Biol Chem 277: 1457–1468.
[10]
Monea S, Jordan BA, Srivastava S, DeSouza S, Ziff EB (2006) Membrane localization of membrane type 5 matrix metalloproteinase by AMPA receptor binding protein and cleavage of cadherins. J Neurosci 26: 2300–2312.
[11]
Kirsch J, Wolters I, Triller A, Betz H (1993) Gephyrin antisense oligonucleotides prevent glycine receptor clustering in spinal neurons. Nature 366: 745–748.
[12]
Neugebauer R, Betz H, Kuhse J (2003) Expression of a soluble glycine binding domain of the NMDA receptor in Escherichia coli. Biochem Biophys Res Commun 305: 476–483.
[13]
Craig AM, Boudin H (2001) Molecular heterogeneity of central synapses: afferent and target regulation. Nature Neurosci 4: 569–578.
[14]
Wetzel M, Rosenberg GA, Cunningham LA (2003) Tissue inhibitor of metalloproteinases-3 and matrix metalloproteinase-3 regulate neuronal sensitivity to doxorubicin-induced apoptosis. Eur J Neurosci 18: 1050–1060.
[15]
Fong DK, Rao A, Crump FT, Craig AM (2002) Rapid synaptic remodeling by protein kinase C: reciprocal translocation of NMDA receptors and calcium/calmodulin-dependent kinase II. J Neurosci 22: 2153–2164.
[16]
MacPherson LJ, Bayburt EK, Capparelli MP, Carroll BJ, Goldstein R, et al. (1997) Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J Med Chem 40: 2525–2532.
[17]
Bertini I, Calderone V, Fragai M, Luchinat C, Mangani S, et al. (2004) Crystal structure of the catalytic domain of human matrix metalloproteinase 10. J Mol Biol 336: 707–16.
[18]
Arendt Y, Banci L, Bertini I, Cantini F, Cozzi R, Del Conte R, Gonnelli L (2007) Catalytic domain of MMP20 (Enamelysin) - the NMR structure of a new matrix metalloproteinase. FEBS Lett 581: 4723–4726.
[19]
Si-Tayeb K, Monvoisin A, Mazzocco C, Lepreux S, Decossas M, et al. (2006) Matrix metalloproteinase 3 is present in the cell nucleus and is involved in apoptosis. Am J Pathol 169: 1390–1401.
[20]
Eguchi T, Kubota S, Kawata K, Mukudai Y, Uehara J, et al. (2008) Novel Transcription Factor-like Function of Human MMP-3 Regulating CTGF/CCN2 Gene. Mol Cell Biol. Jan 2 [Epub ahead of print].
[21]
Siegel SJ, Brose N, Janssen WG, Gasic GP, Jahn R, et al. (1994) Regional, cellular, and ultrastructural distribution of N-methyl-D-aspartate receptor subunit 1 in monkey hippocampus. Proc Natl Acad Sci USA 91: 564–568.
[22]
Nagase H, Fields CG, Fields GB (1994) Design and characterization of a fluorogenic substrate selectively hydrolyzed by stromelysin 1 (matrix metalloproteinase-3). J Biol Chem 269: 20952–20957.
[23]
Herin GA, Aizenman E (2004) Amino-terminal domain regulation of NMDA receptor function. Eur J Pharmacol 500: 101–111.
[24]
Reeves TM, Prins ML, Zhu J, Povlishock JT, Phillips LL (2003) Matrix metalloproteinase inhibition alters functional and structural correlates of deafferentation-induced sprouting in the dentate gyrus. J Neurosci 23: 10182–10189.
[25]
Meighan SE, Meighan PC, Choudhury P, Davis CJ, Olson ML, et al. (2006) Effects of extracellular matrix-degrading proteases matrix metalloproteinases 3 and 9 on spatial learning and synaptic plasticity. J Neurochem 96: 1227–1241.
[26]
VanSaun M, Werle MJ (2000) Matrix metalloproteinase-3 removes agrin from synaptic basal lamina. J Neurobiol 44: 369.
[27]
VanSaun M, Herrera AA, Werle MJ (2003) Structural alterations at the neuromuscular junctions of matrix metalloproteinase 3 null mutant mice. J Neurocytol 32: 1129–1142.
[28]
Neumann FR, Bittcher G, Annies M, Schumacher B, Kroger S, et al. (2001) An alternative amino-terminus expressed in the central nervous system converts agrin to a type II transmembrane protein. Mol Cell Neurosci 17: 208–225.
[29]
Hilgenberg LG, Ho KD, Lee D, O'Dowd DK, Smith MA (2002) Agrin regulates neuronal responses to excitatory neurotransmitters in vitro and in vivo. Mol Cell Neurosci 19: 97–110.
[30]
Sole S, Petegnief V, Gorina R, Chamorro A, Planas AM (2004) Activation of matrix metalloproteinase-3 and agrin cleavage in cerebral ischemia/reperfusion. J Neuropathol exp Neurol 63: 338–349.
[31]
Kim HJ, Fillmore HL, Reeves TM, Phillips LL (2005) Elevation of hippocampal MMP-3 expression and activity during trauma-induced synaptogenesis. Exp Neurol 192: 60–72.
[32]
Kim YS, Kim SS, Cho JJ, Choi OH, Dong H, et al. (2005) Matrix Metalloproteinase-3: A novel signaling proteinase from apoptotic neuronal cells that activates microglia. J Neurosci 25: 3701–3711.
[33]
Murph G, Cockett MI, Ward RV, Docherty AJ (1991) Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase PUMP. Biochem J 277: 277–279.
[34]
Agnihotri R, Crawford HC, Haro H, Matrisian LM, Havrda MC (2001) Osteopontin, a novel substrate for matrix metalloproteinase-3 stromelysin-1 and matrix metalloproteinase-7 matrilysin. J Biol Chem 276: 28261–28267.
[35]
Sage EH, Reed M, Funk SE, Truong T, Steadele M, et al. (2003) Cleavage of the matricellular protein SPARC by matrix metalloproteinase 3 produces polypeptides that influence angiogenesis. J Biol Chem 278: 37849–37857.
[36]
Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, et al. (1995) Metalloproteinase-mediated release of human Fas ligand. J Exp Med 182: 1777–1783.
